Aprea's MDS candidate leads to 95% ORR in Phase Ib/II
Aprea Therapeutics AB (Stockholm, Sweden) reported data from 20 evaluable patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) in a Phase Ib/II trial showing that APR-246 plus Vidaza azacitidine led to an overall...